ICECURE MEDICAL LTD (ICCM)
IL0011224156 - Common Stock
Taking everything into account, ICCM scores 3 out of 10 in our fundamental rating. ICCM was compared to 191 industry peers in the Health Care Equipment & Supplies industry. While ICCM seems to be doing ok healthwise, there are quite some concerns on its profitability. ICCM is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year ICCM has reported negative net income.
ICCM had a negative operating cash flow in the past year.
ICCM had negative earnings in each of the past 5 years.
In the past 5 years ICCM always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -90.28%, ICCM is not doing good in the industry: 80.10% of the companies in the same industry are doing better.
ICCM has a Return On Equity of -124.55%. This is in the lower half of the industry: ICCM underperforms 72.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -90.28% | ||
| ROE | -124.55% | ||
| ROIC | N/A |
ROA(3y)-58.73%
ROA(5y)-55.17%
ROE(3y)-74.66%
ROE(5y)-93.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ICCM has a worse Gross Margin (38.29%) than 67.02% of its industry peers.
ICCM's Gross Margin has been stable in the last couple of years.
ICCM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.29% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.89%
GM growth 5Y-0.83%
2. Health
2.1 Basic Checks
ICCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ICCM has more shares outstanding
ICCM has more shares outstanding than it did 5 years ago.
ICCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -5.42, we must say that ICCM is in the distress zone and has some risk of bankruptcy.
ICCM has a Altman-Z score of -5.42. This is in the lower half of the industry: ICCM underperforms 72.25% of its industry peers.
There is no outstanding debt for ICCM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.42 |
ROIC/WACCN/A
WACC9.35%
2.3 Liquidity
ICCM has a Current Ratio of 3.39. This indicates that ICCM is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.39, ICCM perfoms like the industry average, outperforming 53.40% of the companies in the same industry.
A Quick Ratio of 2.88 indicates that ICCM has no problem at all paying its short term obligations.
ICCM has a Quick ratio (2.88) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.39 | ||
| Quick Ratio | 2.88 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.71% over the past year.
ICCM shows a small growth in Revenue. In the last year, the Revenue has grown by 6.95%.
ICCM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.59% yearly.
EPS 1Y (TTM)25.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)6.95%
Revenue growth 3Y-5.86%
Revenue growth 5Y23.59%
Sales Q2Q%4.23%
3.2 Future
Based on estimates for the next years, ICCM will show a very strong growth in Earnings Per Share. The EPS will grow by 26.52% on average per year.
ICCM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 94.79% yearly.
EPS Next Y5.19%
EPS Next 2Y11.72%
EPS Next 3Y25.99%
EPS Next 5Y26.52%
Revenue Next Year32.03%
Revenue Next 2Y47.25%
Revenue Next 3Y121.01%
Revenue Next 5Y94.79%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ICCM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ICCM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ICCM's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.72%
EPS Next 3Y25.99%
5. Dividend
5.1 Amount
ICCM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ICECURE MEDICAL LTD
NASDAQ:ICCM (6/14/2024, 7:15:12 PM)
After market: 0.782 -0.04 (-4.52%)0.819
+0.06 (+7.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap39.26M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -90.28% | ||
| ROE | -124.55% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.29% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.39 | ||
| Quick Ratio | 2.88 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)25.71%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y5.19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6.95%
Revenue growth 3Y-5.86%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y